MHRA Alert – Falsified Mounjaro KwikPen 15mg Detected in UK
MHRA alert 24 February 2026 · Updated 2 May 2026
Source: MHRA Drug Safety Update, Falsified Mounjaro KwikPen 15mg pre-filled pens. Read the alert itself before acting on it.
Safety Alert: Falsified Mounjaro Identified
The MHRA has identified a falsified version of Mounjaro (tirzepatide) KwikPen 15mg solution for injection supplied through an online pharmacy in the UK. This alert applies to a specific batch and requires immediate awareness among clinical teams and patients.
Key Points
- Falsified product identified with batch number D873576
- Distribution traced to one online pharmacy supplier in the UK
- Mounjaro is a GLP-1 receptor agonist used in the management of type 2 diabetes
- Falsified medicines pose risks including inefficacy, contamination, and adverse effects
Affected Medication
- Mounjaro KwikPen 15mg pre-filled pens (batch D873576)
Recommended Actions
- Check any Mounjaro KwikPen 15mg stock, particularly batch D873576
- Do not supply or administer pens from the identified batch
- Advise patients who may have received this product to contact their healthcare provider immediately
- Report any suspected falsified medicines to the MHRA via the Yellow Card scheme
- Source all medicines through licensed, regulated suppliers only
Further Information
For the full MHRA drug safety update, visit the official MHRA alert page.
Try it on your next event.
Register free, set up an operation with your own call signs, and practise with the training simulation before the real thing.
Already using Eventris? Sign in